Abstract. The advent of various 'omic' technologies has increased expectations in the field of biomarkers. In an attempt to clarify how different strategies may contribute to improving prognostic classification and to identify new predictors of patient outcome we analyzed genomic and transcriptomic profiles in a series of R0 Dukes B and C colorectal carcinomas. We have compared the predictive capability of each approach against conventional clinicopathological and molecular parameters. At a genomic level, gains at 11q including amplification at 11q13 were an indicator of poorer outcome. In transcriptomic analyses we identified 68 genes whose expression levels correlated with survival (p<0.01) and included overexpression of WASF1, NFE2L2, and MMP9, and underexpression of ITGAL, TSC2, and SDF2. Gene expression levels paralleled chromosomal changes only in 56% of the genes, suggesting that, as a general trend, the direct effect of chromosomal copy number changes on gene expression levels is minimal. Classification of tumors by genomic and transcriptomic signatures resulted in non-overlapping subgroups and was not of prognostic value. We conclude that genomic and transcriptomic profiling of colorectal carcinomas may contribute as novel prognostic markers, but it does not improve outcome prediction when global profiles or signatures are considered.
Introduction
Colorectal cancer is the third most common type of neoplasia in both men and women and the second-leading cause of death by cancer in occidental countries (1) . The extent of tumor bowel wall infiltration and lymph node metastases, both included in Dukes' stage and TNM classification systems, are the most important prognostic factors in colorectal cancer (2) . Nevertheless, traditional morphologic criteria based upon pathologist's evaluation are accurate for predicting recurrence only in 50-75% of the patients with non-metastatic invasive colon carcinoma. Therefore there is a need for additional, less subjective, independent factors to better predict outcome.
Multiple genetic aberrations are required for tumor initiation and progression of colorectal cancer, which is one of the best studied systems of multistage human carcinogenesis. Besides the advances in the understanding of the molecular factors involved in this process, the heterogeneity and complexity of the disease make it difficult to apply molecular information to predict the evolution of an individual patient's disease (3) . A major challenge is to integrate information that can describe this complexity so as to facilitate an understanding of the disease mechanisms as well as to guide the development and application of therapies (4) . The advent of various 'omic' technologies has increased expectations in the field of biomarkers, but they have not yet produced widely applicable approaches in prognostic assessment and patient treatment. Four levels of analyses can be considered: genomic, transcriptomic, epigenomic, and proteomic, the first two being the most often applied due to the availability of appropriate methodologies.
Chromosomal aberrations in the form of aneuploidy and structural rearrangements are early markers and probably the most prevalent genetic alteration in colorectal carcinogenesis (5, 6) . Recurrent chromosomal abnormalities often clustered in association patterns are also observed and may be used to classify colorectal cancers (6, 7) . Furthermore, a subset of colorectal tumors with few or no chromosomal alterations are characterized by ubiquitous somatic mutations at repeated sequences (6) (7) (8) . These tumors represent a distinctive pathway of tumor progression in which defects in the DNA mismatch repair machinery underlie the genetic instability expressed as an exacerbated microsatellite instability (MSI).
Conventional G-banding cytogenetics has been instrumental in the identification of the chromosomal alterations associated with malignancy and has provided potential prognostic markers in colorectal cancer (9) . The availability of comparative genomic hybridization (CGH) (10) as an alternative to classic cytogenetics has facilitated karyotyping and nowadays is the (11) (12) (13) (14) . CGH studies have also revealed multiple single chromosomal alterations that are potential prognostic markers (12, 13) , and have contributed to defining patterns of chromosomal aberrations associated with progression (11, 15) . In the last decade technical and bioinformatic advances have made it practical to quantify the expression of thousands of genes using microarrays. This approach has been used to analyze gene expression profiles in a variety of human tumors. One of the most popular applications of transcriptomics has been the generation of biomarkers with predictive competency (16, 17) . Classification of colorectal cancers according to gene expression profiles has been reported to improve prognostic assessment (18) (19) (20) (21) (22) and prediction of response to adjuvant therapy (23) . Besides, these promising results, application of large-scale genomic analyses to the prediction and management of human disease remains excluded from routine clinical practice. Confounding and biased study designs, technologyrelated limitations and statistical and analytical problems pose critical obstacles to the development of reliable predictors using these technologies (16, 17) .
In an attempt to clarify how different strategies may contribute to improve prognostic classification and to identify new predictors of patient outcome we have obtained comprehensive profiles at genomic and transcriptomic levels in a series of R0 Dukes B and C colorectal carcinomas. We have compared the predictive capability of each approach among them and against conventional clinicopathological and molecular parameters. Moreover, we have also investigated the overlapping between each classification.
Materials and methods

Samples.
A series of 50 patients preoperatively diagnosed with colorectal cancer and operated upon with curative or palliative intention between 1996 and 1998 at the Ciutat Sanitària i Universitària de Bellvitge was used in this study. This series included R0 Dukes B or Dukes C colorectal cancer and was part of a larger series of patients prospectively included in a study designed to evaluate the prognostic value of genetic and epigenetic alterations (24) . Clinical and pathological features of the patients are summarized in Table I . The patient and tumor characteristics did not differ significantly between the relapse and no relapse patients, or between treated or non-treated patients.
Surgical specimens were collected at the operating room and immediately taken to the pathology department in ice. Carcinomas and paired normal samples were snap frozen within 2 h after removal and then stored at -80˚C. Tumor sections were cut from microdissected regions of the tumor infiltration front with approximately 75% tumor cell content, as assessed by visual examination of hematoxylin and eosinstained preparations. Special care was taken to discard areas with necrotic tissue or harboring a high inflammatory component. DNA and RNA amenable for genetic analyses were obtained using standard procedures.
Main clinicopathological features and molecular data.
Mutations in the tumor suppressor gene p53, the K-ras oncogene and the presence of microsatellite instability were assessed as previously described (24) .
Comparative genome hybridization (CGH).
This technique was performed as described elsewhere (10) . Briefly, normal and tumor-cell DNA were labeled with SpectrumRed-dUTP and SpectrumGreen-dUTP and equal amounts of normal and tumor labeled probes hybridized to normal metaphase spreads. Chromosomes were counterstained with 4,6-diamino-2-phenylindole (DAPI) for chromosome identification. Slides were analyzed by using a Cytovision Ultra workstation (Applied Imaging, Sunderland, UK). The software calculated the tumor DNA versus normal DNA fluorescent ratios along the length of each chromosome. Ratio values obtained from at least 10 metaphase spreads were averaged, and the resulting profiles were plotted next to the chromosome ideograms.
Gene expression analysis. To generate enough material for technical replicate hybridizations and to increase the representation Table I . Molecular and clinicopathological characteristics of the 50 CRC cases. 
of rare transcripts, total RNA was amplified by RNA Arbitrarily Primed PCR (RAP-PCR) and hybridized to cDNA arrays as previously described (25) . Briefly, RAP-PCR consisted of a reverse transcription step using primer pU6 (5'-GCTTCTGACTTATTCTTGCTCTGAG-3') followed by a PCR using the same primer pU6 consisting of five lowstringency cycles (annealing at 40˚C) and 35 high-stringency cycles (1 annealing at 60˚C). Performance and quality of the reaction were assessed by gel electrophoresis in denaturing sequencing gels and silver staining. The most variable step in using RAP-PCR as a probe was the amplification by PCR (25) . Therefore, we performed two independent RT and from each one, three RAP-PCRs. After checking their quality by gel electrophoresis, we pooled them before labeling. A pool of 12 RAP-PCRs generated from 12 independent normal colon mucosas was used as control.
RAP-PCR products were purified and labeled with dCTPCy3 or dCTP-Cy5 (Amersham Biosciences UK Limited). The tumor sample was labeled with fluorochrome Cy5 and the normal pool was labeled with fluorochrome Cy3. The pooled RAP-PCR from each tumor tissue was cohybridized in duplicate with the pool of normal tissues in poly-L-lysine cDNA microarrays (Hu 4.6K; W.M. Keck Foundation Biotechnology Resource Laboratory, http://keck.med.yale.edu) containing 4608 human cDNAs spotted in duplicate as previously described (25) . A list of the genes covered can be obtained at http://keck.med.yale.edu/dnaarrays/genelists/ QAHU-4_6k_cy.htm. Quality controls, reproducibility and individual gene validation for this design were performed as described in a previous study (25) .
Slides were scanned with a GSI Lumonics ScanArray 4000 and images were analyzed by use of Spot software (CSIRO, Mathematical and Informatics Sciences), and the resulting data were processed to filter out low-quality spots based on spot area and similarity of readings between the two replicates of each gene. Replicate intensities were averaged and normalized. To represent relative intensities, a reference value obtained from the mean of 13 independent hybridizations of the normal pool was used.
Statistical analysis. The effect of the clinicopathological and molecular characteristics on the total number of chromosomal alterations was assessed using a t-test or an ANOVAtest as appropriate. To classify the tumors based on the CGH data (-1 loss, 0 no change and 1 gain) we applied a hierarchical classification algorithm using the Ward criterion. The prognostic value of the variables on survival was evaluated using the log-rank test. Kaplan-Meier estimates were computed to generate the survival curves. Multivariate Cox models that included Dukes' stage were further used to evaluate the prognostic value of the variables. Gene expression data was used to detect differentially expressed genes across all samples, using for this purpose a t-test. Furthermore, the effect of gene expression on the survival was assessed using Cox models allowed to compute hazard ratios (HR). To evaluate significance we computed the score (log-rank) test. Again, multivariate Cox models that included Dukes' stage were used and a Wald test was computed to evaluate significance. Moreover, the effect of the chromosomal alterations on the gene expression were evaluated using a t-test.
The significance level was set to 0.05, or to 0.01 when multiple analyses were performed. All analyses were performed using the statistical package R (http://www.R-project.org).
Results
Chromosomal alterations. The CGH profiles of the 50 colorectal carcinomas are shown in Fig. 1A . To determine the number of chromosomal alterations, losses and gains at p and q arms were scored independently, except for telocentric chromosomes 13, 14, and 15, and chromosome 19, which always showed gains of the whole chromosome. Chromosomes 21, 22 and Y were not considered in this study. The number of alterations per tumor ranged from 0 to 20 (mean 8.8±6.3). Nine tumors (18%) had no alterations, and the 41 remaining (82%) had at least one alteration. The most recurrent alterations were losses of chromosome arms 18q and 17p and gains of 20q and 8q (Table II) . DNA amplification was observed in 19 tumors and affected 6 different loci: 20q (n=10), 11q13 (n=8), 8q24 (n=5), 5q31-q33, 10q22 and 1p36 (in one tumor each). Examples of gene amplification are illustrated in Fig. 1B .
When tumors were classified according to different clinicopathological and molecular data (Table III) , a clear association between the presence of mutation in the p53 gene and the number of chromosome alterations was observed. Even when only one type of alteration was considered: i.e. gains, losses, structural, numerical, amplifications (data not shown), the Losses  18q  33  66  17p  24  48  18p  20  40  8p  19  38  4p  16  32  4q  15  30  14  11  22  15  9  18   Gains  20q  37  74  8q  23  46  13  22  44  7p  19  38  7q  16  32  17q  16  32  20p  13  26  11q  11  22  19  11  22  Xq  10  20  Xp  9 18 Table III . Number of chromosomal alterations in reference to clinicopathological and molecular characterisitics. 
b Left includes tumors of the rectum.
c Amplifications were not included in the computation of the number of chromosomal alterations.
-
statistical association was significant, suggesting the principal role of p53 inactivation in chromosomal instability. Tumors with microsatellite instability showed less chromosomal alterations and the presence of amplifications also correlated with a higher number of chromosomal alterations other than amplifications (Table III) .
Subgrouping of tumors according to genomic profiles. Colorectal cancer is a heterogeneous disease and interactions and confounding factors are likely to mask associations restricted to a homogeneous subgroup of tumors. To circumvent this problem different studies have considered it appropriate to subclassify tumors according to putative genetic pathways. Several strategies and criteria were considered to subgroup tumors. All types of alterations (numerical, structural, losses, gains and amplifications) correlated (data not shown), therefore it was considered inappropriate to classify tumors depending on the prevailing type of chromosomal alteration.
Hierarchical cluster analysis identified two main groups: tumors without alterations and others (data not shown). Tumors with alterations could be also classified into two subgroups essentially differentiated by the number of alterations but no specific signatures of each group were observed (data not shown). Finally, we used criteria adapted from classic cytogenetic studies reported by Dutrillaux (7) . Accordingly, tumors were classified into four groups: microsatellite instability (positive for MSI), normal type (NT) with no MSI and no chromosomal alterations, chromosomal instability monosomic-like (CIN-M) (concomitant loss of 17p and 18q) and chromosomal instability remaining (CIN-R). The main factor differentiating groups was, in addition to the number of chromosomal alterations (Table III) , the frequency of p53 mutations, which was 33% in the MSI and NT groups and 77 and 88% in the CIN-M and CIN-R groups respectively (ANOVA, p=0.005).
Genomic alterations and survival. None of the clinicopathological and molecular parameters previously considered had prognostic value, including Dukes' stage ( Fig. 2A) . The association between chromosomal alterations and patient outcome was investigated. Gains at 11q (n=11), including tumors with amplification in this region, were an indicator of recurrence of the disease (p=0.012) (Fig. 2B) . When only amplifications at 11q13 were considered (n=8), the differences were stressed (p=0.0003), suggesting the principal involvement of this region in conferring poor prognosis. Treatment received (adjuvant chemotherapy and/or radiotherapy) did not appear to modify the outcome. Loss at 12p occurred in four cases and all presented recurrence of the disease (p=0.006) (Fig. 2C) . The statistical significance was maintained when multivariate Cox analysis including the Dukes' stage in the model was performed (Table IV) . No differences in survival were observed when tumors were classified according to the number of chromosomal alterations or grouped by genomic signatures (data not shown). Nevertheless the number of chromosomal alterations appeared to have different associations in CIN-M and CIN-R tumors. In CIN-M tumors a higher number of chromosomal alterations was an indicator of poor prognosis (HR=1.2, CI 95%: 1.0-1.5, p=0.036). Receiver Operating Characteristic Curve analysis offered an optimal cut-off point (Table IV) . In CIN-R tumors there were no statistically significant differences (data not shown).
Gene expression profiles.
For each of the 50 samples, we finally obtained a ratio that is assumed to measure the gene expression level of the CRC relative to the pool of normal tissues. We obtained the lists of the most overexpressed and underexpressed genes (data not shown). The most underexpressed genes in tumor samples were PGM5 (mean log ratio = -3.42±0.81), FUBP3 (mean log ratio = -2.91±0.95), and PMVK (mean log ratio = -2.81±0.67), and the most overexpressed were TPX2 (mean log ratio = 1.38±0.91), GNB1 (mean log ratio = 1.02±0.97) and PDCD5 (mean log ratio = 0.97±0.71).
One of the applications of large scale transcriptomic analyses is the classification of tumors with similar gene expression signatures. The platform used in this study contained 4608 different transcripts. To generate simplified signatures it was considered appropriate to work only with a subset of the genes. Genes exhibiting the highest variability are likely to have a weighty impact in tumor class classification and therefore this criteria was used for gene selection. A standard deviation >0.8 was arbitrarily chosen as cut-off point, resulting in 128 genes available for analysis. Non-supervised hierarchical clustering resulted in four main subgroups of tumors according to the similarities of their expression profiles (data not shown). No differential features in these subgroups were observed in regard to clinicopathological, molecular and genomic information available, suggesting that the resulting transcriptomic signatures did not have a direct relationship with any of the parameters considered.
Gene expression profiles and survival. Using the Cox model we identified 68 genes whose expression levels correlated with disease-free survival (p<0.01) (Fig. 3) . Interestingly, 74% of associations were overexpression (50 out of 68 genes). To illustrate the association Kaplan-Meier survival curves have been traced for a subset of genes after patient classification in tertiles according to the levels of expression (data not shown). The representation includes WASF1, NFE2L2, and MMP9 (in which overexpression was associated with poor outcome) and ITGAL, TSC2, and SDF2 (in which low expression was an indicator of a shorter disease-free survival). Most of the correlations were maintained in multivariate Cox analyses including the Dukes' stage in the model. Results for WASF1 and MMP9 are shown in Table IV .
Classification of patients according to the tumor expression profile (see above) showed different survival rates, although differences did not reach statistical significance (log-rank p=0.07) (Fig. 4) .
Transcriptomic versus genomic profiles. Using ANOVA tests we compared the differential expression of the 4608 genes analyzed among the groups of tumors classified according to genomic profiles (CIN-M, CIN-T, and NT). MSI tumors were not included in this analysis due to their low occurrence (n=3). No statistically significant differences were observed, suggesting that genomic and transcriptomic profiles offer non-overlapping information.
For the most recurrent chromosomal alterations, we also investigated the correlation between copy number changes as detected by CGH and the expression of the genes mapping to the involved genomic region. T-test analyses resulted in a list of genes with p-values <0.05 (data not shown). It is of note that gene expression levels paralleled chromosomal changes only in 56% of the genes, suggesting that, as a general trend, Table IV . Multivariate Cox analysis of disease-free survival. 
Only CIN-M tumors (n=22) were included in this analysis.
b Gene expression levels were categorized in tertiles corresponding to low, intermediate and high values.
the direct effect of chromosomal copy number changes on gene expression levels is negligible.
Discussion
Colorectal cancer is probably the most studied of human solid malignancies. Besides an excellent knowledge of the genetic alterations and the molecular processes involved in carcinogenesis, this effort has not translated into a better prognostic assessment and molecular markers are not yet included in routine clinical settings (26) . Heterogeneity of the disease with multiple progression pathways, the affectation of multiple genes in each of the molecular pathways related with carcinogenesis and the involvement of genome wide disruptive mechanisms (namely, genetic and epigenetic instability) are critical factors that explain this poor outcome. The advent of various 'omic' technologies has increased expectations in the field of biomarkers. Large-scale screening strategies are more likely to generate specific markers applicable to different subsets of tumors.
Thirty to 50% of R0 colorectal cancer patients (Dukes B and C undergoing curative surgery) present recurrence of the disease. In this group of patients the staging system does not allow a precise prediction of recurrence at the individual patient level. Thus, additional prognostic factors are specially needed in this group of patients in which improvement in therapeutic and follow-up strategies may have a deeper impact on survival and quality of life. Here we have investigated genomic and transcriptomic profiles in a series of R0 Dukes B and C colorectal cancer patients. Conventional parameters are ineffectual predictors of outcome in this set of patients. At a molecular level we have identified several alterations that appear as independent prognostic markers.
At a genomic level the distribution of alterations was similar to others found in G-banding (7, 27) and CGH karyotyping (data from various studies summarized in ref. 15 ). The alteration most clearly associated with survival in our series was gain at 11q (in most cases involving amplification at 11q13). Gain at 11q was observed in 11 tumors and was associated with recurrence of the disease (in 8 patients). In Figure 3 . Univariate hazard relative ratio (mean ± CI 95%) calculated using Cox models of gene expression ratio in regard to disease-free survival in colorectal cancer patients. the meta-analysis performed by Diep and coworkers (15) , gains at 11q occurred in approximately 5% of primary carcinomas but were frequent in liver metastases (up to 16%), indicating that this is a late alteration that could be related with distant invasions. Amplification at 11q13 has been reported in many types of epithelial tumors (28) and is a common breakpoint in colorectal cancer (27) . CCDN1 lies in this region and has been found to be amplified in different types of tumors, but does not appear to be the target in colorectal cancer (29) . Therefore, other candidates, possibly EMSY (30) , and RBM14 (31), deserve particular study. Losses at 12p were also associated with poor survival but only affected 4 tumors.
Unsupervised clustering of colorectal tumors according to their transcriptomic signatures often results in groups with different survival rates (18) (19) (20) (21) (22) . Nevertheless, the signatures are quite different among the different investigations even in studies using the same microarray platform. In our analysis transcriptomic profiles also differentiated subgroups with different outcome, but bootstrap analyses indicated the low confidence of the signatures in predicting survival (data not shown).
At a transcriptomic level a large number of predictors of bad outcome were generated. Nevertheless, taking into account the high number of variables considered and the limited number of cases included in this study, the results must be taken very cautiously. A tendency toward overexpression as predictor of poor prognosis was observed. We think that this bias is probably due to the technical limitations of the approach that is likely to have a wider range of change detection for genes that overexpress than genes that underexpress, which very often may be near the limit of detection.
Many of the genes showing correlation with survival have been previously associated with malignant transformation. For instance, WASF1, whose overexpression correlates with a worse survival, plays a critical role downstream of Rac, a Rho-family small GTPase, in regulating the actin cytoskeleton required for membrane ruffling. It has been suggested that WASF1 may be critical for oncogenic transformation downstream of MAP kinase through phosphorylation in response to various external stimuli (32) . NFE2L2, also overexpressed in more aggressive tumors, regulates the cellular oxidative response and constitutive activation of NFE2L2 might predispose to malignant disease in lung (33) . MMP9, overexpressed in tumors of patients with poor survival, is a matrix-degrading enzyme and has been implicated in invasive cell behavior, and a study identified elevated levels of MMP9 mRNA as a predictor of relapse and short survival in colorectal cancer (34) .
ITGAL and TSC2 are genes with lower expression which are associated with poorer survival. ITGAL encodes the integrin · L chain and plays a central role in leukocyte intercellular adhesion through interaction with its ligands, and also functions in lymphocyte co-stimulatory signaling. Therefore it plays a role in immune defense. Regarding cancer, it is more expressed in colorectal Dukes A and B class tumors as compared with Dukes C and D (35) . TSC2 (tuberous sclerosis 2), also known as tuberin, is underexpressed in tumors with poor survival. Its gene product is believed to be a tumor suppressor and is able to stimulate specific GTPases. The protein associates with hamartin (TSC1) in a cytosolic complex. The TSC proteins regulate cell size control due to their involvement in the insulin signaling pathway. Furthermore they are potent positive regulators of the cyclin-dependent kinase inhibitor p27. It seems that TSC genes could trigger deregulation of the stability and localization of the tumor suppressor p27 (36) .
Obviously a validation study using alternative techniques (i.e. real-time RT-PCR) and a different series of patients selected in a prospective setting should be performed to verify the usefulness of these candidate markers. This study is beyond the scope of this paper and the limitations of our setting (namely the size and the high number of candidates considered) preclude obtaining statistically significant conclusions. Future studies should address this issue appropriately.
In summary, CGH and transcriptome microarrays appear as powerful tools to uncover novel candidate predictors of relapse and shorter survival in colorectal cancer of Dukes B and C stages. Nevertheless, global signatures do not appear to constitute faithful markers of patient outcome.
